An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Catalent Publishes Fourth Annual Corporate Responsibility Report Highlighting Achievements While Providing New Record Number of Patient Treatments
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) has released its fourth Corporate Responsibility Report for the fiscal year 2022, ending June 30, showcasing advancements in environmental, social, and governance (ESG) commitments. The company manufactured 80 billion doses across 8,000 products, supporting the launch of 150 new medicines. Catalent has reduced greenhouse gas emissions by 38% from a fiscal 2020 baseline and aims for a 42% reduction by 2030. Additionally, it has committed to zero waste to landfill by 2024, with 60% of sites achieving this milestone. The report also highlights increased diversity efforts and over $1.3 million in philanthropic contributions.
Positive
Manufactured 80 billion doses across approximately 8,000 different products, its highest ever patient-reach.
Enabled customers to launch 150 new medicines and health products in the fiscal year.
Reduced scope 1 and 2 greenhouse gas emissions by 38% from fiscal 2020 baseline.
Aimed for 42% reduction in GHG emissions by 2030.
Achieved a goal of zero waste to landfill by 2024 in 60% of its sites.
Added 38 new Employee Resource Group chapters, enhancing diversity and inclusion.
Negative
None.
SOMERSET, N.J.--(BUSINESS WIRE)--
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today published its fourth Corporate Responsibility Report for its fiscal year 2022, which ended June 30, 2022. The report highlights Catalent's progress against its previously published targets and commitments in the areas of environmental, social, and governance (ESG). It also includes disclosures meeting the standards set by the Sustainability Accounting Standards Board (SASB) and the Task Force on Climate-Related Financial Disclosures (TCFD).
Catalent’s fiscal 2022 saw the company help millions of people lead healthier lives through its development and supply of medicines and consumer health products, manufacturing 80 billion doses across approximately 8,000 different products, its highest ever patient-reach. Additionally, over the 12-month period Catalent enabled its customers to launch 150 new medicines and health products.
"We are proud of the significant progress made in strengthening our corporate responsibility program,” commented Alessandro Maselli, who became President and Chief Executive Officer of Catalent at the beginning of fiscal 2023. “I am committed to continuing to build on our achievements and deliver ambitious ESG goals, which include science-based carbon reduction targets, zero waste to landfill, greater diversity and inclusion across our talent base, and increasing support for the communities we touch. Most importantly, I am eager to drive sustainable breakthroughs in healthcare that improve the lives of patients around the world, and immensely proud of our team’s commitment to work together for maximum impact and success."
The report highlights the progress that Catalent has made in reducing its environmental impact. In the past two years, the company has cut its scope 1 and 2 greenhouse gas (GHG) emissions by 38% from its fiscal 2020 baseline and is on target to meet its goal of a 42% reduction by 2030. Additionally, Catalent is committed to reducing waste, with a goal of zero waste to landfill by 2024, and as of July 2022, 60% of the company's sites have achieved this milestone.
Building on Catalent’s focus to create positive social impact, the report also shows that the company has continued to increase the diversity of its staff across all levels in the business. From fiscal 2021 to fiscal 2022, the company also added 38 new Employee Resource Group chapters, bringing the total to 105, which, among other things, promote inclusivity in the workforce.
Forging links in its surrounding communities, the report shows Catalent made its biggest ever philanthropic contribution, donating more than $1.3 million to nonprofit organizations around the world through grants and matches of employee gifts. The main focus of this support was in science, technology, engineering, and math (STEM) education, as well as serving patient communities and in disaster response, particularly for Ukrainian refugees, and other emergency relief.
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.
With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.
Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.
Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, www.catalent.com.
More products. Better treatments. Reliably supplied.™
